MA43709A - Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations - Google Patents

Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations

Info

Publication number: MA43709A
Authority: MA; Morocco
Prior art keywords: empagliflozin; pharmaceutical composition; composition consisting; pharmaceutical; composition
Prior art date: 2016-03-16

Application number

MA043709A

Other languages

English (en)

Inventor

Uli Broedl

Afshin Salsali

Hans-Juergen Woerle

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-16

Filing date

2017-03-13

Publication date

2018-11-28

2017-03-13 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2018-11-28 Publication of MA43709A publication Critical patent/MA43709A/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA043709A 2016-03-16 2017-03-13 Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations MA43709A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662309008P	2016-03-16	2016-03-16
US201662420062P	2016-11-10	2016-11-10

Publications (1)

Publication Number	Publication Date
MA43709A true MA43709A (fr)	2018-11-28

Family

ID=58267120

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA043709A MA43709A (fr)	2016-03-16	2017-03-13	Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations

Country Status (13)

Country	Link
US (6)	US20170266152A1 (fr)
EP (1)	EP3429595A1 (fr)
JP (4)	JP7161405B2 (fr)
KR (6)	KR20240095321A (fr)
CN (4)	CN118903166A (fr)
AU (3)	AU2017233889B2 (fr)
BR (1)	BR112018016001A2 (fr)
CA (1)	CA3017992A1 (fr)
CL (1)	CL2018002532A1 (fr)
MA (1)	MA43709A (fr)
MX (4)	MX2018011088A (fr)
PH (2)	PH12021552046A1 (fr)
WO (1)	WO2017157816A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EP4684831A3 (fr)	2009-02-13	2026-03-11	Boehringer Ingelheim International GmbH	Inhibiteur de sglt2 pour améliorer la régulation glycémique
HUE050287T2 (hu)	2009-02-13	2020-11-30	Boehringer Ingelheim Int	SGLT2-inhibitort, DPP-IV-inhibitort és adott esetben egy további antidiabetikus hatóanyagot tartalmazó gyógyászati készítmény és alkalmazásai
UY32919A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (fr)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
TR201901110T4 (tr)	2013-04-05	2019-02-21	Boehringer Ingelheim Int	Empagliflozinin terapötik kullanımları.
CA2812016A1 (fr)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
HK1215378A1 (zh)	2013-04-18	2016-08-26	勃林格殷格翰国际有限公司	药物组合物、治疗方法及其用途
AU2017357589B2 (en)	2016-11-10	2023-05-11	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CN111163782A (zh) *	2017-10-02	2020-05-15	普克塞尔公司	治疗射血分数保留型心力衰竭的方法
SG11202007172YA (en)	2018-06-06	2020-08-28	Metavant Sciences Gmbh	Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (fr)	2018-06-14	2019-12-19	Poxel	Comprime pellicule comprenant un derive de triazine destine a etre utilise dans le traitement du diabete
WO2020016335A1 (fr)	2018-07-19	2020-01-23	Astrazeneca Ab	Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
WO2020039394A1 (fr)	2018-08-24	2020-02-27	Novartis Ag	Nouvelles combinaisons de médicaments
CN109846898A (zh) *	2019-02-01	2019-06-07	同济大学	恩格列净在制备治疗和/或预防心肌梗死的药物中的应用
IT201900006624A1 (it) *	2019-05-08	2020-11-08	Moret Giannino	Combinazione di canrenone e enalapril per uso nella terapia dei pazienti diabetici.
EA202191858A1 (ru) *	2019-06-12	2021-11-12	Фармакосмос Холдинг А/С	Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
EP4021507A1 (fr) *	2019-08-30	2022-07-06	AstraZeneca AB	Méthodes de traitement de l'insuffisance cardiaque à fraction d'éjection réduite avec la dapagliflozine
WO2021049612A1 (fr) *	2019-09-13	2021-03-18	国立大学法人富山大学	Médicament pour améliorer la rétention de fluide dans une insuffisance cardiaque aiguë
BR112022016360A2 (pt) *	2020-02-17	2022-10-04	Boehringer Ingelheim Vetmedica Gmbh	Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
EP4376829A1 (fr)	2021-07-28	2024-06-05	Boehringer Ingelheim Vetmedica GmbH	Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de maladies cardiaques chez des mammifères non humains à l'exclusion de félins, en particulier des canidés
JP7396579B2 (ja) *	2022-01-31	2023-12-12	壽製薬株式会社	左室駆出率が保たれた心不全に対する医薬組成物
WO2024240632A1 (fr)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Polythérapie et/ou prévention de maladies cardiaques chez des mammifères non humains comprenant un ou plusieurs inhibiteurs de sglt -2 et du pimobendane et/ou du telmisartan

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7723309B2 (en) *	2005-05-03	2010-05-25	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) *	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
CL2008002427A1 (es) *	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
NZ598318A (en) *	2009-09-30	2014-02-28	Boehringer Ingelheim Int	Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
US20130035298A1 (en) *	2011-07-08	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9192617B2 (en) *	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) *	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (fr) *	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
US20140303097A1 (en) *	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HK1215378A1 (zh) *	2013-04-18	2016-08-26	勃林格殷格翰国际有限公司	药物组合物、治疗方法及其用途

2017
- 2017-03-13 CN CN202410254242.7A patent/CN118903166A/zh active Pending
- 2017-03-13 MX MX2018011088A patent/MX2018011088A/es unknown
- 2017-03-13 KR KR1020247017944A patent/KR20240095321A/ko not_active Ceased
- 2017-03-13 JP JP2018548341A patent/JP7161405B2/ja active Active
- 2017-03-13 MA MA043709A patent/MA43709A/fr unknown
- 2017-03-13 CN CN201780018512.2A patent/CN109069525A/zh active Pending
- 2017-03-13 KR KR1020237023405A patent/KR20230111262A/ko not_active Ceased
- 2017-03-13 KR KR1020187029941A patent/KR20180122004A/ko not_active Ceased
- 2017-03-13 KR KR1020237004848A patent/KR20230028565A/ko not_active Ceased
- 2017-03-13 BR BR112018016001-6A patent/BR112018016001A2/en not_active Application Discontinuation
- 2017-03-13 CA CA3017992A patent/CA3017992A1/fr active Pending
- 2017-03-13 CN CN202410254246.5A patent/CN118286237A/zh active Pending
- 2017-03-13 US US15/456,631 patent/US20170266152A1/en not_active Abandoned
- 2017-03-13 KR KR1020237004928A patent/KR20230028568A/ko not_active Ceased
- 2017-03-13 PH PH1/2021/552046A patent/PH12021552046A1/en unknown
- 2017-03-13 CN CN202410254338.3A patent/CN118286238A/zh active Pending
- 2017-03-13 EP EP17710524.4A patent/EP3429595A1/fr active Pending
- 2017-03-13 KR KR1020257036831A patent/KR20250161667A/ko active Pending
- 2017-03-13 AU AU2017233889A patent/AU2017233889B2/en active Active
- 2017-03-13 WO PCT/EP2017/055767 patent/WO2017157816A1/fr not_active Ceased
2018
- 2018-07-17 US US16/037,052 patent/US20180318251A1/en not_active Abandoned
- 2018-09-05 CL CL2018002532A patent/CL2018002532A1/es unknown
- 2018-09-13 MX MX2024005626A patent/MX2024005626A/es unknown
- 2018-09-13 MX MX2022008491A patent/MX2022008491A/es unknown
- 2018-09-13 PH PH12018501969A patent/PH12018501969A1/en unknown
- 2018-09-13 MX MX2021010329A patent/MX2021010329A/es unknown
2019
- 2019-02-26 US US16/285,774 patent/US20190350894A1/en not_active Abandoned
2020
- 2020-06-18 US US16/904,709 patent/US20210059974A1/en not_active Abandoned
2021
- 2021-08-04 JP JP2021128431A patent/JP7454531B2/ja active Active
2022
- 2022-03-16 US US17/696,075 patent/US20220211659A1/en not_active Abandoned
- 2022-10-05 AU AU2022246392A patent/AU2022246392B2/en active Active
- 2022-10-14 JP JP2022165221A patent/JP2023001136A/ja active Pending
2024
- 2024-03-11 JP JP2024037260A patent/JP2024083347A/ja active Pending
- 2024-08-29 AU AU2024216447A patent/AU2024216447A1/en active Pending
- 2024-11-14 US US18/947,116 patent/US20250073200A1/en active Pending

Also Published As

Publication number	Publication date
MX2021010329A (es)	2021-10-13
PH12021552046A1 (en)	2022-06-27
US20180318251A1 (en)	2018-11-08
US20250073200A1 (en)	2025-03-06
KR20230028565A (ko)	2023-02-28
CA3017992A1 (fr)	2017-09-21
JP2023001136A (ja)	2023-01-04
MX2018011088A (es)	2018-11-22
AU2017233889B2 (en)	2022-07-07
WO2017157816A1 (fr)	2017-09-21
US20220211659A1 (en)	2022-07-07
KR20230028568A (ko)	2023-02-28
CN118286238A (zh)	2024-07-05
BR112018016001A2 (en)	2018-12-18
KR20250161667A (ko)	2025-11-17
MX2024005626A (es)	2024-05-24
JP2019508453A (ja)	2019-03-28
JP2024083347A (ja)	2024-06-21
EP3429595A1 (fr)	2019-01-23
US20210059974A1 (en)	2021-03-04
AU2017233889A1 (en)	2018-08-09
AU2024216447A1 (en)	2024-09-19
CN118903166A (zh)	2024-11-08
MX2022008491A (es)	2022-08-02
KR20240095321A (ko)	2024-06-25
JP2021181461A (ja)	2021-11-25
JP7161405B2 (ja)	2022-10-26
PH12018501969A1 (en)	2019-06-17
KR20230111262A (ko)	2023-07-25
CL2018002532A1 (es)	2019-01-04
KR20180122004A (ko)	2018-11-09
CN118286237A (zh)	2024-07-05
US20190350894A1 (en)	2019-11-21
AU2022246392A1 (en)	2022-10-27
CN109069525A (zh)	2018-12-21
US20170266152A1 (en)	2017-09-21
AU2022246392B2 (en)	2024-09-19
JP7454531B2 (ja)	2024-03-22

Publication	Publication Date	Title
MA43709A (fr)	2018-11-28	Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
EP3675863A4 (fr)	2021-01-27	Composition pharmaceutique comprenant de la sépiaptérine et ses utilisations
EP3691657A4 (fr)	2021-07-21	Compositions d'acide nucléique-polypeptide et utilisations de celles-ci
EP3434285A4 (fr)	2019-10-30	Composition pharmaceutique et ses utilisations
EP3370770A4 (fr)	2019-06-12	Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
EP3548000A4 (fr)	2019-12-04	Compositions pharmaceutiques d'atropine
EP3500255A4 (fr)	2020-03-25	Compositions pharmaceutiques ophtalmiques et utilisations associées
MA47816A (fr)	2020-01-15	Composition pharmaceutique comprenant du sélexipag
EP3307766A4 (fr)	2019-06-12	Protéine d'interleukine-7 modifiée et ses utilisations
MA46742A (fr)	2019-09-18	Composition pharmaceutique, méthodes de traitement et leurs utilisations
MA43308A (fr)	2018-10-03	Molécules d'anticorps se liant à april et leurs utilisations
EP3603620A4 (fr)	2020-03-25	Composition de liposome et composition pharmaceutique
EP3678666A4 (fr)	2021-06-09	Activateur d'akt3 spécifique et ses utilisations
EP3307772A4 (fr)	2019-02-20	Anticorps spécifiques de tgf-bêta 3 et procédés et utilisations associés
EP3412660A4 (fr)	2019-07-10	Dérivé de sulfonamide et composition pharmaceutique le contenant
EP3518971A4 (fr)	2020-05-13	Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
EP3685828A4 (fr)	2021-08-11	Composition pharmaceutique ophtalmique, trousse ophtalmique et application pharmaceutique associée
MA47494A (fr)	2019-12-25	Nouvelles utilisations d'anticorps anti-sirpg
EP3412292A4 (fr)	2019-02-27	Utilisation de méthoxatine, d'un dérivé et/ou d'un sel de cette dernière contre le syndrome de gougerot-sjögren, et composition pharmaceutique
MA44665A (fr)	2019-02-20	Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
EP3675874A4 (fr)	2021-06-09	Composition pharmaceutique pour le traitement des chéloïdes et ses utilisations
MA43361A (fr)	2018-10-10	Composition pour le soin et la protection de cultures
EP3496748A4 (fr)	2020-01-15	Anticorps anti-o2 et utilisations associées
EP3777866A4 (fr)	2022-01-05	Composition pharmaceutique et application de cette dernière
EP3509627A4 (fr)	2020-05-06	Inhibiteurs de l'histone déméthylase-1 spécifiques de la lysine et leurs utilisations